Table 2 Comparisons of observing indexes between pre-treatment and post-treatment in two groups [(\(\overline x\)± s), n (%), M (P25,P75)]
Variables | NPWT | Non-NPWT |
|---|---|---|
Number of patients | ||
Pre-treatment | 40 | 20 |
Post-treatment | 40 | 20 |
ULA, cm2 | ||
Pre-treatment | 10.6 ± 3.1 | 10.4 ± 2.9 |
Post-treatment | 7.9 ± 2.9 | 9.3 ± 3.0 |
FPG, mmol/L | ||
Pre-treatment | 11.1 ± 2.9 | 10.9 ± 3.1 |
Post-treatment | 8.3 ± 2.1b | 8.5 ± 1.9b |
ABI | ||
Pre-treatment | 1.07 ± 0.13 | 1.12 ± 0.14 |
Post-treatment | 1.08 ± 0.13 | 1.11 ± 0.13 |
CRP, mg/dl | ||
Pre-treatment | 39.2 ± 12.4 | 38.8 ± 11.6 |
Post-treatment | 18.8 ± 7.9b | 30.5 ± 12.4a |
WBC, ×109 | ||
Pre-treatment | 11.2 ± 4.4 | 10.3 ± 3.9 |
Post-treatment | 8.5 ± 2.2b | 9.3 ± 2.7a |
ESR, mm/h | ||
Pre-treatment | 39.7 ± 16.5 | 40.1 ± 17.3 |
Post-treatment | 33.8 ± 15.7 | 35.6 ± 16.4 |
Hb, g/L | ||
Pre-treatment | 114 ± 16 | 116 ± 15 |
Post-treatment | 113 ± 15 | 116 ± 14 |
Alb, g/L | ||
Pre-treatment | 36.1 ± 3.5 | 35.7 ± 3.3 |
Post-treatment | 35.8 ± 3.4 | 36.8 ± 3.5 |
T-IL-1β, pg/ml | ||
Pre-treatment | 15.7 ± 7.2 | 14.2 ± 6.9 |
Post-treatment | 6.1 ± 3.4b | 9.8 ± 4.8a |
T-IL-6, pg/ml | ||
Pre-treatment | 80.3 ± 16.6 | 78.1 ± 17.9 |
Post-treatment | 40.7 ± 11.3b | 57.4 ± 15.2a |
T-IL-4, pg/ml | ||
Pre-treatment | 4.9 ± 1.5 | 5.1 ± 1.8 |
Post-treatment | 10.2 ± 3.2b | 8.5 ± 2.9a |
T-IL-10, pg/ml | ||
Pre-treatment | 5.3 ± 2.7 | 5.7 ± 2.5 |
Post-treatment | 16.4 ± 3.5b | 9.4 ± 2.6a |
T-miR-155 | ||
Pre-treatment | 6.83 (2.15–15.72) | 7.15 (2.52–19.07) |
Post-treatment | 4.12 (1.22–14.85)a | 6.32 (1.96–17.45) |
T-FGF7 | ||
Pre-treatment | 0.504 ± 0.119 | 0.491 ± 0.122 |
Post-treatment | 0.796 ± 0.125a | 0.524 ± 0.127 |
